Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net revenue:
Total net revenues	$ 2,884	$ 2,266	$ 5,071	$ 5,002
Cost of goods sold	1,523	991	2,685	2,140
Gross margin	1,361	1,275	2,386	2,862
Operating expenses:
Research and development	431	487	1,009	1,043
Depreciation and amortization	64	51	116	101
Selling, general and administrative	2,070	1,854	4,418	3,853
Total operating expenses	2,565	2,392	5,543	4,997
Loss from operations	(1,204)	(1,117)	(3,157)	(2,135)
Other income (expense):
Interest expense	(6)	(11)	(13)	(24)
Interest income	1	3	3	6
Extinguishment of PPP loan				482
Other income (expense), net	72	(1)	63	8
Total other income (expense):	67	(9)	53	472
Net loss	(1,137)	(1,126)	(3,104)	(1,663)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(66)	(60)	(129)	(119)
Net loss attributable to Nephros, Inc. shareholders	$ (1,203)	$ (1,186)	$ (3,233)	$ (1,782)
Net loss per common share, basic and diluted	$ (0.12)	$ (0.12)	$ (0.31)	$ (0.18)
Weighted average common shares outstanding, basic and diluted	10,299,148	9,943,026	10,265,267	9,913,196
Comprehensive loss:
Other comprehensive income (loss), foreign currency translation adjustments, net of tax		$ 2	$ (3)	$ (4)
Comprehensive loss	(1,137)	(1,124)	(3,107)	(1,667)
Comprehensive loss attributable to noncontrolling interest	(66)	(60)	(129)	(119)
Comprehensive loss attributable to Nephros, Inc. shareholders	(1,203)	(1,184)	(3,236)	(1,786)
Product [Member]
Net revenue:
Total net revenues	2,839	2,196	5,016	4,908
Royalty and Other revenues [Member]
Net revenue:
Total net revenues	$ 45	$ 70	$ 55	$ 94